Last reviewed · How we verify
Diosmin / Hesperidin — Competitive Intelligence Brief
marketed
Bioflavonoid / Venoactive agent
Cardiovascular / Vascular disorders
Small molecule
Live · refreshed every 30 min
Target snapshot
Diosmin / Hesperidin (Diosmin / Hesperidin) — Pirogov Russian National Research Medical University. Diosmin and hesperidin are bioflavonoids that strengthen blood vessel walls and improve microcirculation by reducing capillary fragility and enhancing venous tone.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Diosmin / Hesperidin TARGET | Diosmin / Hesperidin | Pirogov Russian National Research Medical University | marketed | Bioflavonoid / Venoactive agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Bioflavonoid / Venoactive agent class)
- Pirogov Russian National Research Medical University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Diosmin / Hesperidin CI watch — RSS
- Diosmin / Hesperidin CI watch — Atom
- Diosmin / Hesperidin CI watch — JSON
- Diosmin / Hesperidin alone — RSS
- Whole Bioflavonoid / Venoactive agent class — RSS
Cite this brief
Drug Landscape (2026). Diosmin / Hesperidin — Competitive Intelligence Brief. https://druglandscape.com/ci/diosmin-hesperidin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab